AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16308008 — intervention group
Group type: COMPARATOR
Intervention: Atmospheric air, 1.5 atmospheres absolute
Number of subjects: 64
Study 12617335 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 9
Study 12617335 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 9
Study 10554126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral supplementation (calcium and phosphorus) with vitamin D (500 IU/day)
Number of subjects: 70
Study 10554126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral supplementation (calcium and phosphorus) with vitamin D (1000 IU/day)
Number of subjects: 70
Study 10554126 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented breast milk
Number of subjects: 70
Study 10554126 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 70
Study 8707495 — intervention group
Group type: EXPERIMENTAL
Intervention: Component approaches, checklist, and scale assessment
Number of subjects: 0
Study 8707495 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 1856145 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of amikacin (15 mg/kg) given iv over 30 min
Number of subjects: 0
Study 1856145 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of tobramycin (4.5 mg/kg) given iv over 30 min
Number of subjects: 0
Study 1856145 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h continuous infusion of amikacin
Number of subjects: 0
Study 1856145 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h continuous infusion of tobramycin
Number of subjects: 0
Study 1856145 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections of amikacin (7.5 mg/kg)
Number of subjects: 0
Study 1856145 — intervention group
Group type: EXPERIMENTAL
Intervention: Three injections of tobramycin (1.5 mg/kg)
Number of subjects: 0
Study 1856145 — intervention group
Group type: COMPARATOR
Intervention: Single injection of amikacin
Number of subjects: 0
Study 6343143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 52
Study 6343143 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 52
Study 6343143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and chlorpheniramine in combination
Number of subjects: 52
Study 30468136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness group therapy (MGT)
Number of subjects: 0
Study 30468136 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (mostly cognitive-behavioral therapy)
Number of subjects: 0
Study 30670359 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) at individualized targets (either caudate or nucleus accumbens) for 3 months
Number of subjects: 7
Study 30670359 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 7
Study 28767146 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (RW) 375 ml/d for 4 weeks
Number of subjects: 22
Study 25602465 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐CBT (standard cognitive‐behavioral treatment)
Number of subjects: 70
Study 25602465 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐CBT (culturally accommodated cognitive‐behavioral treatment)
Number of subjects: 70
Study 25602465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural moderators (ethnic identity, familism)
Number of subjects: 70
Study 24471459 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil 2% lotion
Number of subjects: 40
Study 24471459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20934835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR + Contingency Management (CM)
Number of subjects: 134
Study 20934835 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Non-Contingency Management (non-CM)
Number of subjects: 134
Study 19581463 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 10 mg/kg
Number of subjects: 38
Study 19581463 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 20 mg/kg
Number of subjects: 38
Study 19581463 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 40 mg/kg
Number of subjects: 38
Study 19581463 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour dosing interval
Number of subjects: 38
Study 19581463 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour dosing interval
Number of subjects: 38
Study 19581463 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-hour infusion time
Number of subjects: 38
Study 19581463 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour infusion time
Number of subjects: 38
Study 16735935 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 300 microg/day
Number of subjects: 77
Study 16735935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 15031238 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls risk alert card with information brochure, exercise programme, education programme, and hip protectors
Number of subjects: 626
Study 15031238 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 626
Study 11432692 — intervention group
Group type: COMPARATOR
Intervention: Buspirone
Number of subjects: 63
Study 11432692 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone
Number of subjects: 63
Study 11432692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 9446373 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transjugular intrahepatic porto‐systemic shunt (TIPS)
Number of subjects: 20
Study 8174828 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cold pressor test (4 degrees C)
Number of subjects: 7
Study 8174828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenergic blockers (propranolol and phentolamine)
Number of subjects: 7
Study 8174828 — intervention group
Group type: COMPARATOR
Intervention: Control cold pressor test (37 degrees C)
Number of subjects: 7
Study 8174828 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful stimuli or adrenergic blockers
Number of subjects: 7
Study 3146403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy after positive CCK test
Number of subjects: 174
Study 3146403 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomy for uncomplicated calculous gallbladder disease
Number of subjects: 174
Study 30739288 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3 and home exercise (HE)
Number of subjects: 173
Study 30739288 — intervention group
Group type: COMPARATOR
Intervention: 800 IU vitamin D3 and no HE (Control)
Number of subjects: 173
Study 30739288 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D3 and HE
Number of subjects: 173
Study 30739288 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3 and no HE
Number of subjects: 173
Study 28323893 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (3 weekly sessions of 35 minutes moderate intensity walking/running followed by 25 minutes strength training)
Number of subjects: 91
Study 28323893 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 91
Study 28323893 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 91
Study 26152322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 10 mg/d
Number of subjects: 30
Study 26152322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 30 mg/d
Number of subjects: 30
Study 26152322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26152322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone therapies (10 mg/d and 30 mg/d)
Number of subjects: 30
Study 23274785 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN monotherapy
Number of subjects: 214
Study 23274785 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN±lamivudine
Number of subjects: 214
Study 21649862 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only
Number of subjects: 52
Study 21649862 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus DASH diet
Number of subjects: 52
Study 21649862 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 52
Study 18308788 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (mean dose: 14.7 mg; range: 10-30 mg)
Number of subjects: 18
Study 18308788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16834582 — intervention group
Group type: EXPERIMENTAL
Intervention: Benson Relaxation Technique (BRT) combined with medication
Number of subjects: 50
Study 16834582 — intervention group
Group type: COMPARATOR
Intervention: Only medication (control group)
Number of subjects: 50
Study 15042104 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]WAY‐100635 in recovered depressed subjects
Number of subjects: 32
Study 15042104 — intervention group
Group type: COMPARATOR
Intervention: [(11)C]WAY‐100635 in healthy controls
Number of subjects: 32
Study 11709742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense ADoc regimen (4 cycles of Doxorubicin 50 mg/m², Docetaxel 75 mg/m² i.v. day 1, q day 15 or 22; G-CSF day 3-15 only for the dose-dense schedule)
Number of subjects: 292
Study 11709742 — intervention group
Group type: EXPERIMENTAL
Intervention: ADoc + Tamoxifen
Number of subjects: 292
Study 11709742 — intervention group
Group type: COMPARATOR
Intervention: ADoc
Number of subjects: 292
Study 9821453 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum lithium levels (0.8‐1.0 mmol L‐1)
Number of subjects: 91
Study 9821453 — intervention group
Group type: COMPARATOR
Intervention: Low serum lithium levels (0.5‐0.8 mmol L‐1)
Number of subjects: 91
Study 9821453 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (both high and low levels)
Number of subjects: 91
Study 9821453 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum lithium levels
Number of subjects: 91
Study 9821453 — intervention group
Group type: COMPARATOR
Intervention: Low serum lithium levels
Number of subjects: 91
Study 7815279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin formulation (delivered volumes of 80-160 microL)
Number of subjects: 12
Study 2679333 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroperative digital manipulation before removal
Number of subjects: 17
Study 2679333 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic removal
Number of subjects: 17
Study 16335673 — intervention group
Group type: COMPARATOR
Intervention: Adrenocortical carcinoma
Number of subjects: 27
Study 16335673 — intervention group
Group type: COMPARATOR
Intervention: Adrenocortical adenoma
Number of subjects: 27
Study 16335673 — intervention group
Group type: COMPARATOR
Intervention: Adrenal metastases
Number of subjects: 27
Study 31026353 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterweight-Plus weight management programme
Number of subjects: 1000
Study 25724407 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral palonosetron (0.50 mg) with oral dexamethasone
Number of subjects: 738
Study 25724407 — intervention group
Group type: COMPARATOR
Intervention: IV palonosetron (0.25 mg) with oral dexamethasone
Number of subjects: 738
Study 25724407 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral palonosetron (0.50 mg)
Number of subjects: 738
Study 25724407 — intervention group
Group type: COMPARATOR
Intervention: IV palonosetron (0.25 mg)
Number of subjects: 738
Study 23453674 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 17
Study 23453674 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 17
Study 23453674 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone + Phenytoin
Number of subjects: 17
Study 23453674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22020357 — intervention group
Group type: COMPARATOR
Intervention: Placebo + fluoxetine (≤80 mg/d of fluoxetine)
Number of subjects: 54
Study 22020357 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine + fluoxetine (≤75 and ≤40 mg/d, respectively)
Number of subjects: 54
Study 22020357 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine + fluoxetine (≤200 and ≤40 mg/d, respectively)
Number of subjects: 54
Study 19635614 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg with CE 0.625 mg
Number of subjects: 3397
Study 19635614 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 40 mg with CE 0.45 mg
Number of subjects: 3397
Study 19635614 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 10 mg with CE 0.625 mg
Number of subjects: 3397
Study 19635614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3397
Study 16757491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK) and usual care
Number of subjects: 304
Study 16757491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK) and mandatory invasive study < or = 24 h
Number of subjects: 304
Study 16757491 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI with 300 mg loading dose of clopidogrel
Number of subjects: 304
Study 15300231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CS) 3 mg/kg/day intravenously, with subsequent oral dosing
Number of subjects: 80
Study 15300231 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CS) plus Methotrexate (MTX) 15 mg/m2 on day 1, and 10 mg/m2 on days 3, 6, and 11
Number of subjects: 80
Study 11760331 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent study method of physical assessment
Number of subjects: 20
Study 11760331 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture method of instruction
Number of subjects: 20
Study 9480608 — intervention group
Group type: EXPERIMENTAL
Intervention: Eve 20 (20 micrograms ethinylestradiol EE, 500 micrograms norethisterone)
Number of subjects: 118
Study 9480608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovelle (20 micrograms ethinylestradiol EE, 150 micrograms Desogestrel)
Number of subjects: 118
Study 8138651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular buprenorphine
Number of subjects: 75
Study 8138651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pentazocine
Number of subjects: 75
Study 8138651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular nefopam
Number of subjects: 75
Study 3313041 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily)
Number of subjects: 4081
Study 3313041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4081
Study 3313041 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 4081
Study 29545639 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG analysis in DLB patients
Number of subjects: 0
Study 29545639 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG analysis in DLB and PDD patients
Number of subjects: 0
Study 29545639 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 0
Study 29545639 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia groups (DLB, AD, PDD)
Number of subjects: 0
Study 30931750 — intervention group
Group type: EXPERIMENTAL
Intervention: DI‐15 High‐Fidelity Electronic Earplugs
Number of subjects: 15
Study 30931750 — intervention group
Group type: EXPERIMENTAL
Intervention: Music PRO Electronic Earplugs
Number of subjects: 15
Study 30931750 — intervention group
Group type: EXPERIMENTAL
Intervention: Other hearing protection devices (HPDs)
Number of subjects: 15
Study 30931750 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic HPDs
Number of subjects: 15
Study 23897052 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiplex gel (carboxymethylcellulose/polyethylene oxide gel) applied during surgery
Number of subjects: 68
Study 23897052 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 68
Study 23102853 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced invitation letter
Number of subjects: 800
Study 23102853 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation letter (control group)
Number of subjects: 800
Study 23102853 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group at diagnosis
Number of subjects: 800
Study 21122466 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol
Number of subjects: 0
Study 21122466 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38
Number of subjects: 0
Study 21122466 — intervention group
Group type: COMPARATOR
Intervention: VIP
Number of subjects: 0
Study 18206149 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stress condition
Number of subjects: 56
Study 18206149 — intervention group
Group type: COMPARATOR
Intervention: Auditory control condition
Number of subjects: 56
Study 16831781 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session group intervention
Number of subjects: 26
Study 16831781 — intervention group
Group type: COMPARATOR
Intervention: Standard care control condition
Number of subjects: 26
Study 12897592 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10900154 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (5 mg/m(2)/week)
Number of subjects: 10
Study 10900154 — intervention group
Group type: COMPARATOR
Intervention: No immunosuppressive treatment (Control)
Number of subjects: 10
Study 8970308 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised curriculum intervention
Number of subjects: 38
Study 1474534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (2000 mg/day)
Number of subjects: 298
Study 1474534 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (1000 mg/day)
Number of subjects: 298
Study 1474534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 298
Study 1474534 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 298
Study 6386412 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meals with added fat (potatoes, rice, apples)
Number of subjects: 14
Study 6386412 — intervention group
Group type: COMPARATOR
Intervention: Test meals without added fat (potatoes, rice, apples)
Number of subjects: 14
Study 31544569 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected ametropia (myopia)
Number of subjects: 24296
Study 31544569 — intervention group
Group type: COMPARATOR
Intervention: Gender
Number of subjects: 24296
Study 31544569 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 24296
Study 31544569 — intervention group
Group type: COMPARATOR
Intervention: Ethnicity
Number of subjects: 24296
Study 29973132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 80
Study 29973132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27265390 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 1114
Study 27265390 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 1114
Study 24811969 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-factor PCC (Beriplex P/N)
Number of subjects: 35
Study 24811969 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-factor PCC (Profilnine SD)
Number of subjects: 35
Study 24811969 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 35
Study 22218138 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial nerve mobilization
Number of subjects: 60
Study 22218138 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intermittent ultrasound therapy)
Number of subjects: 60
Study 20185423 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided antimicrobial treatment
Number of subjects: 550
Study 20185423 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 550
Study 20185423 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided treatment (advised)
Number of subjects: 550
Study 20185423 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided treatment (overruled)
Number of subjects: 550
Study 20185423 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 550
Study 17852871 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiprofessional education programme
Number of subjects: 93
Study 17852871 — intervention group
Group type: COMPARATOR
Intervention: Regular information (Control)
Number of subjects: 93
Study 16213926 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term immunotherapy (STI) with molecular standardized allergens (ALK(7), n = 24) plus anti-allergic drugs
Number of subjects: 48
Study 16213926 — intervention group
Group type: COMPARATOR
Intervention: Anti-allergic drugs alone (n = 24)
Number of subjects: 48
Study 12145716 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B colloidal dispersion (ABCD; 6 mg/kg/day)
Number of subjects: 174
Study 12145716 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (AmB; 1.0-1.5 mg/kg/day)
Number of subjects: 174
Study 11409825 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinged ankle‐foot orthosis (HAFO)
Number of subjects: 30
Study 11409825 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior leaf spring (PLS)
Number of subjects: 30
Study 11409825 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid ankle‐foot orthosis (SAFO)
Number of subjects: 30
Study 9037575 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (LD) plus bromocriptine (Br)
Number of subjects: 50
Study 9037575 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (LD) alone
Number of subjects: 50
Study 8379178 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde Venous Perfusion (RVP)
Number of subjects: 20
Study 8379178 — intervention group
Group type: COMPARATOR
Intervention: Systemic intravenous infusions (SVI)
Number of subjects: 20
Study 3510660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole, 200 mg twice daily for male partners
Number of subjects: 117
Study 3510660 — intervention group
Group type: COMPARATOR
Intervention: Placebo for male partners
Number of subjects: 117
Study 29168473 — intervention group
Group type: EXPERIMENTAL
Intervention: Yangxin Tongmai Formula (YTF) administered orally for 60 days
Number of subjects: 40
Study 29168473 — intervention group
Group type: EXPERIMENTAL
Intervention: Yangxin Tongmai Formula (YTF)
Number of subjects: 40